BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Cevik O, Li D, Baljinnyam E, Manvar D, Pimenta EM, Waris G, Barnes BJ, Kaushik-Basu N. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. J Biol Chem 2017;292:21676-89. [PMID: 29079574 DOI: 10.1074/jbc.M117.792721] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
2 Shimizu JF, Lima CS, Pereira CM, Bittar C, Batista MN, Nazaré AC, Polaquini CR, Zothner C, Harris M, Rahal P, Regasini LO, Jardim ACG. Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry. Sci Rep 2017;7:16127. [PMID: 29170411 DOI: 10.1038/s41598-017-16336-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
3 Ariza-Mateos A, Díaz-Toledano R, Block TM, Prieto-Vega S, Birk A, Gómez J. Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral Replication. Antimicrob Agents Chemother 2016;60:925-35. [PMID: 26621620 DOI: 10.1128/AAC.02511-15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Tovo PA, Calitri C, Scolfaro C, Gabiano C, Garazzino S. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World J Gastroenterol 2016; 22(4): 1382-1392 [PMID: 26819507 DOI: 10.3748/wjg.v22.i4.1382] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
5 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
6 Kayesh MEH, Ezzikouri S, Sanada T, Chi H, Hayashi Y, Rebbani K, Kitab B, Matsuu A, Miyoshi N, Hishima T, Kohara M, Tsukiyama-Kohara K. Oxidative Stress and Immune Responses During Hepatitis C Virus Infection in Tupaia belangeri. Sci Rep 2017;7:9848. [PMID: 28852124 DOI: 10.1038/s41598-017-10329-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 2016;100:545-57. [PMID: 26921345 DOI: 10.1189/jlb.2A1215-561R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
8 Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. J Interferon Cytokine Res 2017;37:278-86. [PMID: 28440692 DOI: 10.1089/jir.2016.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Tapp H, Ludden T, Shade L, Thomas J, Mohanan S, Leonard M. Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system. Prev Med Rep 2020;17:101036. [PMID: 31970042 DOI: 10.1016/j.pmedr.2019.101036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kaushik-Basu N, Ratmanova NK, Manvar D, Belov DS, Cevik O, Basu A, Yerukhimovich MM, Lukyanenko ER, Andreev IA, Belov GM, Manfroni G, Cecchetti V, Frick DN, Kurkin AV, Altieri A, Barreca ML. Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents. Eur J Med Chem 2016;122:319-25. [PMID: 27376494 DOI: 10.1016/j.ejmech.2016.06.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015; 21(38): 10790-10810 [PMID: 26478671 DOI: 10.3748/wjg.v21.i38.10790] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
12 Giannakopoulou E, Pardali V, Frakolaki E, Siozos V, Myrianthopoulos V, Mikros E, Taylor MC, Kelly JM, Vassilaki N, Zoidis G. Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species. Medchemcomm 2019;10:991-1006. [PMID: 31303998 DOI: 10.1039/c9md00200f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lee YM, Duh Y, Wang ST, Lai MM, Yuan HS, Lim C. Using an Old Drug to Target a New Drug Site: Application of Disulfiram to Target the Zn-Site in HCV NS5A Protein. J Am Chem Soc 2016;138:3856-62. [PMID: 26928525 DOI: 10.1021/jacs.6b00299] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
14 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
15 Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int 2019;39:1986-98. [PMID: 31172639 DOI: 10.1111/liv.14168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Krol E, Wandzik I, Pastuch-Gawolek G, Szewczyk B. Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars. Molecules 2018;23:E1547. [PMID: 29954068 DOI: 10.3390/molecules23071547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Lougiakis N, Frakolaki E, Karmou P, Pouli N, Marakos P, Madan V, Bartenschlager R, Vassilaki N. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism. Chem Biol Drug Des 2017;90:352-67. [PMID: 28245093 DOI: 10.1111/cbdd.12966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
19 Aghbash PS, Hemmat N, Nahand JS, Shamekh A, Memar MY, Babaei A, Baghi HB. The role of Th17 cells in viral infections. Int Immunopharmacol 2021;91:107331. [PMID: 33418239 DOI: 10.1016/j.intimp.2020.107331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Hussein NR. The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy. Mediterr J Hematol Infect Dis 2017;9:e2017005. [PMID: 28105296 DOI: 10.4084/MJHID.2017.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
21 Cabral MS, Santos TPS, Santos PL, Schinoni MI, Oliveira IS, Pereira AB, Atta AM, Sousa-Atta MLB. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection. Cytokine 2018;102:200-5. [PMID: 28969940 DOI: 10.1016/j.cyto.2017.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
22 Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS One 2016;11:e0153895. [PMID: 27100663 DOI: 10.1371/journal.pone.0153895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Groopman JD. Environmental health in the biology century: Transitions from population to personalized prevention. Exp Biol Med (Maywood) 2019;244:728-33. [PMID: 30895818 DOI: 10.1177/1535370219837903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 McGonigle K, Carley T, Hoff C. Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population. J Racial Ethn Health Disparities 2018;5:1052-8. [PMID: 29288470 DOI: 10.1007/s40615-017-0453-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
26 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
27 Guo S, Kapp ME, Beltran DM, Cardona CY, Caster DJ, Reichel RR, Fogo AB. Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection. Am J Clin Pathol 2021;156:399-408. [PMID: 33623996 DOI: 10.1093/ajcp/aqaa238] [Reference Citation Analysis]
28 Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C. Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterol 2017;4:e000130. [PMID: 28461903 DOI: 10.1136/bmjgast-2016-000130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
29 Krol E, Pastuch-Gawolek G, Chaubey B, Brzuska G, Erfurt K, Szewczyk B. Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds. Molecules 2018;23:E1435. [PMID: 29899276 DOI: 10.3390/molecules23061435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Lasfar A, Zloza A, Cohen-Solal KA. IFN-lambda therapy: current status and future perspectives. Drug Discov Today 2016;21:167-71. [PMID: 26552337 DOI: 10.1016/j.drudis.2015.10.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
31 Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. Aliment Pharmacol Ther. 2016;44:145-156. [PMID: 27199103 DOI: 10.1111/apt.13673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
32 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
33 Sghaier I, Mouelhi L, Ghazoueni E, Brochot E, Almawi WY, Yacoubi-Loueslati B. Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population. Cytokine 2017;99:297-304. [PMID: 28823914 DOI: 10.1016/j.cyto.2017.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Stubbs A, Naylor P, Ravindran K, Benjaram S, Reddy N, Mutchnick S, May E, Ehrinpreis M, Mutchnick M. Racial diversity in mortality and morbidity in urban patients with hepatitis C. J Viral Hepat 2016;23:439-46. [PMID: 26818494 DOI: 10.1111/jvh.12504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Gong W, Guo X, Zhang Y. Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5. Yonsei Med J 2018;59:1181-9. [PMID: 30450852 DOI: 10.3349/ymj.2018.59.10.1181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]